3 recruiting, 2 active not recruiting, 2 completed, 2 terminated. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 3, Active not recruiting 2, Completed 2, Terminated 1 |
| Phase 1 | 3 | Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Phase 2 | Recruiting | City of Hope Medical Center | 56 | 2026-02-11 | 2026-03-05 |
| Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy Chimeric Antigen Receptor T-Cell Therapy, Odronextamab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | University of California, Davis | 34 | 2025-08-07 | 2026-07-08 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Carboplatin - Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | David Bond, MD | 37 | 2023-06-29 | 2026-07-20 |
| Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2023-04-01 | 2023-01-13 | |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma CD47 Antagonist ALX148, Lenalidomide, Rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2021-10-13 | 2026-09-18 |
| Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2020-07-27 | 2025-01-28 |
| Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy Electronic Health Record Review - Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Unknown | M.D. Anderson Cancer Center | 150 | 2020-04-02 | 2023-11-14 | |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 23 | 2020-03-04 | 2026-02-27 |
| Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma External Beam Radiation Therapy, Pembrolizumab - Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 17 | 2018-02-01 | 2026-01-13 |
Lymphoma, Large B-Cell, Diffuse (9) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Composite Lymphoma (1) · Disease Progression (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoma (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Lymphoma, Non-Hodgkin (10) · Lymphoma, B-Cell (9) · Disease Attributes (2) · Hematologic Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Chronic Disease (1)
Cyclophosphamide (3) · Specimen Handling (3) · axicabtagene ciloleucel (3) · Biopsy (2) · CT-P10 (2) · Carboplatin (2) · Cytarabine (2) · Etoposide (2) · Ifosfamide (2) · Interleukin 1 Receptor Antagonist Protein (2) · Lenalidomide (2) · Leukapheresis (2) · Magnetic Resonance Spectroscopy (2) · Receptors, Interleukin-6 (2) · Rituximab (2)
M.D. Anderson Cancer Center (4) · University of California, Davis (2) · City of Hope Medical Center (1) · David Bond, MD (1) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (11)
Chelsea C Pinnix (1) · David A Bond, MD (1) · Francisco J Hernandez-ILizaliturri (1) · John M Timmerman, MD (1) · Joseph M Tuscano (1) · Joseph M Tuscano, MD (1) · Karamjeet S Sandhu (1) · Paolo Strati (1) · Paolo Strati, MD (1) · Raphael E Steiner (1) · Victor Chow (1)
P30CA093373 (2), P30CA033572 (1)